Abstract

BackgroundNon-neutralising antibodies to the envelope glycoprotein are elicited during acute HIV-1 infection and are abundant throughout the course of disease progression. Although these antibodies appear to have negligible effects on HIV-1 infection when assayed in standard neutralisation assays, they have the potential to exert either inhibitory or enhancing effects through interactions with complement and/or Fc receptors. Here we report that non-neutralising antibodies produced early in response to HIV-1 infection can enhance viral infectivity.ResultsWe investigated this complement-mediated antibody-dependent enhancement (C'-ADE) of early HIV infection by carrying out longitudinal studies with primary viruses and autologous sera derived sequentially from recently infected individuals, using a T cell line naturally expressing the complement receptor 2 (CR2; CD21). The C'-ADE was consistently observed and in some cases achieved infection-enhancing levels of greater than 350-fold, converting a low-level infection to a highly destructive one. C'-ADE activity declined as a neutralising response to the early virus emerged, but later virus isolates that had escaped the neutralising response demonstrated an increased capacity for enhanced infection by autologous antibodies. Moreover, sera with autologous enhancing activity were capable of C'ADE of heterologous viral isolates, suggesting the targeting of conserved epitopes on the envelope glycoprotein. Ectopic expression of CR2 on cell lines expressing HIV-1 receptors was sufficient to render them sensitive to C'ADE.ConclusionsTaken together, these results suggest that non-neutralising antibodies to the HIV-1 envelope that arise during acute infection are not 'passive', but in concert with complement and complement receptors may have consequences for HIV-1 dissemination and pathogenesis.

Highlights

  • HIV envelope-specific antibodies can be detected in the blood of infected individuals within a few weeks of infection [1,2]

  • We have examined the effects of complement on antibodies and viruses from patients with acute HIV-1 infection using cell lines with a complement receptors (CRs) (CR2)

  • We investigated a role for enhancing antibodies in early HIV infection by carrying out longitudinal studies with primary viruses and autologous sera derived sequentially from recently infected individuals, using a T cell line naturally expressing complement receptor 2 (CR2)

Read more

Summary

Introduction

HIV envelope-specific antibodies can be detected in the blood of infected individuals within a few weeks of infection [1,2]. HIV can activate complement in the absence of antibodies through direct interactions between the envelope proteins gp and gp120, and complement cascade components C1q and MBL [13,14,15,16,17], while bound antibodies amplify complement activation and the deposition of complement fragments on the viral surface [18,19,20]. Non-neutralising antibodies to the envelope glycoprotein are elicited during acute HIV-1 infection and are abundant throughout the course of disease progression These antibodies appear to have negligible effects on HIV-1 infection when assayed in standard neutralisation assays, they have the potential to exert either inhibitory or enhancing effects through interactions with complement and/or Fc receptors. Many antibodies produced by HIV-1-infected individuals bind to the viral envelope glycoprotein, yet fail to neutralise the virus These non-neutralising responses are usually considered ‘silent’ because they have little effect on HIV-1 infectivity in traditional neutralisation assays. Complement activation can lead to both 1 as well as a consideration in the evaluation of envelope-based vaccines

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call